That drug - Natrecor - looked to be a blockbuster, but many doctors avoid it because of worries that it might raise the risk of death.
但许多医生因为担心该药物可能增加患者死亡风险而避而不用。
The bad news came from a test of Natrecor, a drug that had meteoric sales after its approval in 2001 because it was the only medicine that seemed to help shortness of breath.
坏消息则来自于对奈西立肽做的测验。这种药自2001年得到认可后,销量惊人,因为当时它被认为是唯一可能治疗呼吸急促的药。
One out of every six people hospitalized with heart failure were given Natrecor until it came under a cloud in 2005 when studies suggested it raised the risk of death and kidney problems.
当时,每六个因心衰住院的患者中有一个会被要求服用奈西立肽。直到2005年,多项研究证实,奈西立肽会增加死亡和肾脏问题的风险。到这时,它才失去了市场。
One out of every six people hospitalized with heart failure were given Natrecor until it came under a cloud in 2005 when studies suggested it raised the risk of death and kidney problems.
当时,每六个因心衰住院的患者中有一个会被要求服用奈西立肽。直到2005年,多项研究证实,奈西立肽会增加死亡和肾脏问题的风险。到这时,它才失去了市场。
应用推荐